Gastric and intestinal diffuse large B-cell lymphomas are clinically and immunophenotypically different. An immunohistochemical and clinical study

Histopathology

Volumn 51, Issue 5, 2007, Pages 697-703

  Connor, J ^a   Ashton Key, M ^a,b  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Bcl 6; CD10; Diffuse large B cell lymphoma; Extranodal; Gastric; Immunohistochemistry; Intestinal; Mucosa associated lymphoid tissue

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PREDNISOLONE; VINCRISTINE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; CANCER CYTODIAGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; FISHER EXACT TEST; GERMINAL CENTER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; KAPLAN MEIER METHOD; LOG RANK TEST; MALE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STOMACH LYMPHOMA; STUDENT T TEST; SURVIVAL RATE; SURVIVAL TIME; TISSUE SECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHILD; FEMALE; GERMINAL CENTER; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INTESTINAL NEOPLASMS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; STOMACH NEOPLASMS;

EID: 35348873741     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2007.02855.x     Document Type: Article

References (17)

1. Armitage JO, Weisenberger DD. New Approach to classifying non-Hodgkin's lymphomas: clinical features of the major histological subtypes. Non Hodgkin's Lymphoma Classification Project. J. Clin. Oncol. 1998 16 2780 2795.
2. Pileri SA, Dirnhofer S, Went PH et al. Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification. Histopathology 2002 41 482 509.
3. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000 4052 503 511.
4. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004 103 275 282.
5. Barrans S, Carter I, Owen R et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002 99 1136 1143.
6. Rosenwald A, Wright G, Chan WC et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N. Engl. J. Med. 2002 346 1937 1947.
7. Gascoyne RD, Adomat SA, Krajewski S et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997 90 244 251.
8. Saez A, Artiga M, Rosado A et al. Building an outcome predictor model for diffuse large B-cell lymphoma. Am. J. Pathol. 2004 164 613 622.
9. M Hill ME, MacLennan KA, Cunningham DC et al. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. Blood 1996 88 1046 1051.
10. Hermine O, Haioun C, Lepage E et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 1996 87 265 272.
11. Ponzoni M, Ferreri AJ, Pruneri G et al. Prognostic values of bcl-6, CD10 and CD38 immunoreactivity in stage I-II gastric lymphomas: identification of a subset of CD10+ large B-cell lymphomas with a favourable outcome. Int. J. Cancer 2003 106 288 291.
12. Ohshima K, Kawasaki C, Muta H et al. CD10 and Bcl10 expression in diffuse large B-cell lymphoma: CD10 is a marker of improved prognosis. Histopathology 2001 39 156 162.
13. Go J, Yang W, Ree H. CD10 expression in primary intestinal large B-cell lymphomas. Arch. Pathol. Lab. Med. 2002 126 956 960.
14. Takeshita M, Iwashita A, Kurihara K et al. Histological and immunohistological findings and prognosis of 40 cases of gastric large B-cell lymphomas. Am. J. Surg. Pathol. 2000 24 1641 1649.
15. Chen Y-W, Hu X-T, Liang AC et al. High BCL6 expression predicts better prognosis, independent of BCL6 translocation status, a translocation partner, or BCL-6-deregulating mutations in gastric lymphoma. Blood 2006 8 2373 2383.
16. Leval LD, Harris NL. Variability in immunophenotype in diffuse large B-cell lymphoma and its clinical relevance. Histopathology 2003 43 509 528.
17. Anchez E, Chacon I, Munoz E et al. Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins. J. Clin. Oncol. 1998 16 1931 1939.